Chemistry:Sovleplenib

From HandWiki

Sovleplenib is an investigational new drug that is being evaluated by Hutchison MediPharma[1] for the treatment of immune thrombocytopenia (ITP)[2] and warm antibody autoimmune hemolytic anemia (WAIHA).[3] It has also been shown preclinically to have activity against B-cell lymphoma.[4] Sovleplenib is a tyrosine-protein kinase SYK inhibitor.[4]

Clinical trials

Sovleplenib has completed a phase 3 clinical trial for ITP.[5] Another phase 3 trial for WAIHA is on going.[6]

References

  1. ↑ "Sovleplenib - Hutchison MediPharma". AdisInsight. Springer Nature Switzerland AG. https://adisinsight.springer.com/drugs/800040817. 
  2. ↑ "Efficacy and Safety of Syk and BTK Inhibitors in Immune Thrombocytopenia: A Comprehensive Review of Emerging Evidence". Mediators of Inflammation 2025. 2025. doi:10.1155/mi/5578929. PMID 40385351. 
  3. ↑ "Beneath the surface in autoimmune hemolytic anemia: pathogenetic networks, therapeutic advancements and open questions". Frontiers in Immunology 16. 2025. doi:10.3389/fimmu.2025.1624667. PMID 40821796. 
  4. ↑ 4.0 4.1 "HMPL-523, a novel SYK inhibitor showed anti-tumor activities in vitro and in vivo.". Blood 128 (22): 3970. December 2016. doi:10.1182/blood.V128.22.3970.3970. 
  5. ↑ Clinical trial number NCT05029635 for "Phase III Study on HMPL-523 for Treatment of ITP" at ClinicalTrials.gov
  6. ↑ Clinical trial number NCT05535933 for "HMPL-523 (Sovleplenib) in the Treatment of Warm Antibody Autoimmune Hemolytic Anemia" at ClinicalTrials.gov



Retrieved from "https://handwiki.org/wiki/index.php?title=Chemistry:Sovleplenib&oldid=4582625"